Real-world effectiveness and safety of second-line lenvatinib and sorafenib after atezolizumab plus bevacizumab in patients with HCC: A multi-center analysis from the LINK research network in Korea

Lee, M. J.; Lim, S.; Shim, J. Y.; Kim, D. K.; Kim, K. -P.; Kim, K.; Ryoo, B. -Y.; Choi, W. -M.; Kim, H. -J.; Lee, S. -H.; Kang, G.; Kang, M.; Cha, W. C.; Hong, J. Y.; Jeong, W. K.; Ju, S. K.; Won, J.; Lee, D.; Ahn, J.; Kim, D. -Y.

doi:10.1016/j.annonc.2025.10.178

상세 보기

Real-world effectiveness and safety of second-line lenvatinib and sorafenib after atezolizumab plus bevacizumab in patients with HCC: A multi-center analysis from the LINK research network in Korea

Lee, M. J.;
Lim, S.;
Shim, J. Y.;
Kim, D. K.;
Kim, K. -P.;
... Cha, W. C.;
... Hong, J. Y.;
... Jeong, W. K.;
외 12명

Citations

WEB OF SCIENCE

0

제목: Real-world effectiveness and safety of second-line lenvatinib and sorafenib after atezolizumab plus bevacizumab in patients with HCC: A multi-center analysis from the LINK research network in Korea

저자: Lee, M. J.; Lim, S.; Shim, J. Y.; Kim, D. K.; Kim, K. -P.; Kim, K.; Ryoo, B. -Y.; Choi, W. -M.; Kim, H. -J.; Lee, S. -H.; Kang, G.; Kang, M.; Cha, W. C.; Hong, J. Y.; Jeong, W. K.; Ju, S. K.; Won, J.; Lee, D.; Ahn, J.; Kim, D. -Y.

DOI: 10.1016/j.annonc.2025.10.178

발행일: 2025-12

유형: Meeting Abstract

저널명: Annals of Oncology

권: 36

@

상세 보기